Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides (Q34160291)

31 July 2017

1 reference

title

Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides (English)

1 reference

31 July 2017

Nathalie Dias

1

1 reference

31 July 2017

C A Stein

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

European Journal of Pharmaceutics and Biopharmaceutics

31 July 2017

published in

1 reference

31 July 2017

volume

54

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

263-269

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Antisense therapy in oncology: new hope for an old idea?

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Antisense therapeutics: is it as simple as complementary base recognition?

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Biochemical and biological effects of nonionic nucleic acid methylphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

A simple method for delivering morpholino antisense oligos into the cytoplasm of cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

In vitro transport and delivery of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Mechanism of oligonucleotide release from cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Delivery of oligonucleotides into mammalian cells by anionic peptides: comparison between monomeric and dimeric peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Trojan peptides: the penetratin system for intracellular delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Improved intracellular delivery of oligonucleotides by square wave electroporation

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Life-or-death decisions by the Bcl-2 protein family.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Bcl-2 family proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Investigations of antisense oligonucleotides targeted against bcl-2 RNAs.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2802%2900060-7

7 January 2021

10.1016/S0939-6411(02)00060-7

Identifiers

DOI

1 reference

31 July 2017

1 reference